On March 24, 2022 Formosa Pharmaceuticals reported the approval of a resolution by the boards of directors of both Formosa Pharmaceuticals and EirGenix, Inc. for the co-development of anticancer ADC, TSY-0110 (EG12043) (Press release, Formosa Pharmaceuticals, MAR 24, 2022, View Source [SID1234630879]). This agreement strengthens the existing relationship between both companies and fortifies TSY-0110’s clinical development pathway and subsequent licensing prospects.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
TSY-0110 is a biosimilar of the antibody-drug conjugate, Kadcyla, which combines Herceptin with the cytotoxic payload, mertansine, to achieve an enhanced antitumor effect with manageable safety profile. Kadcyla, developed by Roche Pharmaceuticals, was first approved by the US FDA in 2013 for the treatment of HER2-positive metastatic breast cancer (MBC) and later gained additional approval for early breast cancer (EBC) in 2019. Kadcyla is currently utilized as a single-agent 2nd-line treatment for breast cancer and is being tested in numerous clinical trials as a combination agent with other biologics and chemotherapeutics. Kadcyla’s global sales from 2021 is approximately USD $2.1 billion and annual sales are expected to remain strong.
Per the terms of the agreement, Formosa Pharmaceuticals will receive upfront and milestone payments for a total of USD $30 million from EirGenix in exchange for profit-sharing rights to TSY-0110. Additionally, EirGenix is named the exclusive supplier of its Herceptin biosimilar (EG12014) as the key intermediate toward the manufacturing of TSY-0110. EirGenix, who recently completed a USD $110 million cash capital increase and $175 million private placement, submitted Marketing Authorization (MAA) and Biologics Licensing (BLA) Applications to the EMA (EU) and FDA (US), respectively, for EG12014 with marketing partner, Sandoz AG, in December, 2021.
Formosa Pharmaceuticals’ chairman and founder, Dr. CY Cheng, said, "We are pleased to broaden our relationship with EirGenix for the development of HER2-related cancer therapies and leverage their proven clinical development expertise. We look forward to sharing the commercial benefits."